ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline
Authors:
Open Access
- 7 February 2024
- journal article
- research article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 25 (3-4) , 388-399
Abstract
Introduction Upacicalcet is a novel injectable calcimimetic. This phase 3 multicenter open-label study aimed to assess the long-term efficacy and safety of upacicalcet in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). Methods Japanese HD patients with serum intact parathyroid hormone (iPTH) levels >240 pg/mL and corrected calcium (cCa) levels ≥8.4 mg/dL were enrolled. Upacicalcet with a dose range of 25–300 µg was administered after each dialysis for 52 weeks. The main efficacy endpoint was the percentage of patients achieving the target iPTH level (60–240 pg/mL). Results A total of 157 patients were enrolled, of whom 138 completed the study. Overall, 94.2% of patients achieved the target serum iPTH level at week 52. Neither symptomatic hypocalcemia nor cCa level <7.5 mg/dL occurred despite the negligible increase of concomitant vitamin D receptor activators and calcium carbonate. Upacicalcet improved the control of serum phosphate (P) and calcium levels regardless of baseline PTH levels and decreased intact fibroblast growth factor-23 levels. The largest parathyroid glands shrank, irrespective of their baseline volume or prior calcimimetic usage. Upacicalcet was well-tolerated, with no adverse events requiring dose reduction. Conclusion This is the first study to show that a calcimimetic improves serum P and cCa control without inducing severe hypocalcemia in patients with iPTH levels ≤300 pg/mL. Upacicalcet is efficacious in HD patients with mild-to-severe SHPT, with few safety concerns.Keywords
This publication has 31 references indexed in Scilit:
- Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trialeClinicalMedicine, 2022
- Amyotrophic lateral sclerosisThe Lancet, 2022
- Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosisJournal of Neurology, 2021
- Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosisMuscle & Nerve, 2020
- Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis – Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial)Regenerative Therapy, 2019
- Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open‐Access ALS Clinical Trials cohortMuscle & Nerve, 2018
- Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosisJournal of Neurology, 2016
- ALSFRS-R score and its ratio: A useful predictor for ALS-progressionJournal of the Neurological Sciences, 2008
- Dose-ranging study of riluzole in amyotrophic lateral sclerosisThe Lancet, 1996